SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Omega Therapeutics, Inc. – ‘10-K’ for 12/31/23 – ‘XML’

On:  Thursday, 3/28/24, at 4:31pm ET   ·   For:  12/31/23   ·   Accession #:  950170-24-38094   ·   File #:  1-40657

Previous ‘10-K’:  ‘10-K/A’ on 3/24/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   13 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/28/24  Omega Therapeutics, Inc.          10-K       12/31/23   94:15M                                    Donnelley … Solutions/FA

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.94M 
 3: EX-10.12    Material Contract                                   HTML     31K 
 4: EX-10.13    Material Contract                                   HTML     31K 
 5: EX-10.18    Material Contract                                   HTML     59K 
 6: EX-10.20    Material Contract                                   HTML     62K 
 7: EX-10.22    Material Contract                                   HTML     59K 
 8: EX-10.33    Material Contract                                   HTML   1.45M 
 2: EX-10.9     Material Contract                                   HTML    220K 
 9: EX-23.1     Consent of Expert or Counsel                        HTML     27K 
14: EX-97       Clawback Policy re: Recovery of Erroneously         HTML     43K 
                Awarded Compensation                                             
10: EX-31.1     Certification -- §302 - SOA'02                      HTML     33K 
11: EX-31.2     Certification -- §302 - SOA'02                      HTML     33K 
12: EX-32.1     Certification -- §906 - SOA'02                      HTML     30K 
13: EX-32.2     Certification -- §906 - SOA'02                      HTML     29K 
16: R1          Document and Entity Information                     HTML    101K 
17: R2          Consolidated Balance Sheets                         HTML    130K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     46K 
19: R4          Consolidated Statements of Operations and           HTML     95K 
                Comprehensive Loss                                               
20: R5          Consolidated Statements of Stockholders' Equity     HTML     69K 
21: R6          Consolidated Statements of Cash Flows               HTML    128K 
22: R7          Pay vs Performance Disclosure                       HTML     39K 
23: R8          Insider Trading Arrangements                        HTML     33K 
24: R9          Nature of the Business and Basis of Presentation    HTML     42K 
25: R10         Summary of Significant Accounting Policies          HTML     89K 
26: R11         Marketable Securities                               HTML     50K 
27: R12         Prepaid Expenses and Other Current Assets           HTML     52K 
28: R13         Property and Equipment, Net                         HTML     54K 
29: R14         Accrued Expenses                                    HTML     50K 
30: R15         Term Loan                                           HTML     75K 
31: R16         Fair Value of Financial Instruments                 HTML     99K 
32: R17         Commitments and Contingencies                       HTML     99K 
33: R18         License Agreements                                  HTML     53K 
34: R19         Collaboration Agreement                             HTML     46K 
35: R20         Preferred and Common Stock                          HTML     39K 
36: R21         Equity Incentive Plans                              HTML    115K 
37: R22         Net Loss Per Share Attributable to Common           HTML     53K 
                Stockholders                                                     
38: R23         Income Taxes                                        HTML     99K 
39: R24         Related Party Transactions                          HTML     47K 
40: R25         Employee Benefits                                   HTML     32K 
41: R26         Summary of Significant Accounting Policies          HTML    148K 
                (Policies)                                                       
42: R27         Summary of Significant Accounting Policies          HTML     33K 
                (Tables)                                                         
43: R28         Marketable Securities (Tables)                      HTML     45K 
44: R29         Prepaid Expenses and Other Current Assets (Tables)  HTML     52K 
45: R30         Property and Equipment, Net (Tables)                HTML     52K 
46: R31         Accrued Expenses (Tables)                           HTML     49K 
47: R32         Term Loan (Tables)                                  HTML     64K 
48: R33         Fair Value of Financial Instruments (Tables)        HTML    150K 
49: R34         Commitments and Contingencies (Tables)              HTML     77K 
50: R35         Equity Incentive Plans (Tables)                     HTML    102K 
51: R36         Net Loss Per Share Attributable to Common           HTML     54K 
                Stockholders (Tables)                                            
52: R37         Income Taxes (Tables)                               HTML     91K 
53: R38         Nature of the Business and Basis of Presentation -  HTML     53K 
                Additional Information (Details)                                 
54: R39         Summary of Significant Accounting Policies -        HTML     65K 
                Additional Information (Details)                                 
55: R40         Summary of Significant Accounting Policies -        HTML     37K 
                Summary of Estimated Useful Life of Each Asset                   
                Category (Details)                                               
56: R41         Marketable Securities - Summary of Marketable       HTML     39K 
                Securities (Details)                                             
57: R42         Marketable Securities - Additional Information      HTML     35K 
                (Details)                                                        
58: R43         Prepaid Expenses and Other Current Assets -         HTML     42K 
                Summary of Prepaid Expenses and other Current                    
                Assets (Details)                                                 
59: R44         Property and Equipment, Net - Summary of Property   HTML     46K 
                and Equipment, Net (Details)                                     
60: R45         Property and Equipment, Net - Additional            HTML     29K 
                Information (Details)                                            
61: R46         Accrued Expenses - Summary of Accrued Expenses      HTML     41K 
                (Details)                                                        
62: R47         Term Loan - Additional Information (Details)        HTML     82K 
63: R48         Term Loan - Summary of Outstanding Term Loan        HTML     36K 
                Balance (Details)                                                
64: R49         Term Loan - Summary of Interest Expense Recognized  HTML     35K 
                Related to Term loan (Details)                                   
65: R50         Term Loan - Schedule of Principal Amount in         HTML     41K 
                Connection With Term Loan (Details)                              
66: R51         Fair Value of Financial Instruments - Summary of    HTML     47K 
                Fair Value of Financial Instruments (Details)                    
67: R52         Fair Value of Financial Instruments - Additional    HTML     35K 
                Information (Details)                                            
68: R53         Fair Value of Financial Instruments - Summary of    HTML     42K 
                Significant Quantitative Inputs Used to Determine                
                Valuation of Success Fee Obligation (Details)                    
69: R54         Fair Value of Financial Instruments - Summary of    HTML     40K 
                Fair Values of Success Fee Obligation (Details)                  
70: R55         Commitments and Contingencies - Additional          HTML    165K 
                Information (Details)                                            
71: R56         Commitments and Contingencies - Summary of          HTML     34K 
                Components of Lease Expense (Details)                            
72: R57         Commitments and Contingencies - Summary of          HTML     32K 
                Weighted Average Remaining Lease Term And Discount               
                Rate Related to Leases (Details)                                 
73: R58         Commitments and Contingencies - Summary of          HTML     32K 
                Supplemental Cash Flow Information Relating to                   
                Leases (Details)                                                 
74: R59         Commitments and Contingencies - Summary of          HTML     46K 
                Estimated Minimum Lease Payments (Details)                       
75: R60         License Agreements - Additional Information         HTML     86K 
                (Details)                                                        
76: R61         Collaboration Agreement - Additional Information    HTML     49K 
                (Details)                                                        
77: R62         Redeemable Convertible Preferred Stock -            HTML     34K 
                Additional Information (Details)                                 
78: R63         Preferred and Common Stock - Additional             HTML     73K 
                Information (Details)                                            
79: R64         Equity Incentive Plans - Additional Information     HTML     82K 
                (Details)                                                        
80: R65         Equity Incentive Plans - Summary of Stock-based     HTML     34K 
                Compensation Expense (Details)                                   
81: R66         Equity Incentive Plans - Summary of Assumptions     HTML     39K 
                Used in Black-Scholes Option-pricing Model for                   
                Stock Options (Details)                                          
82: R67         Equity Incentive Plans - Summary of Option          HTML     87K 
                Activity (Details)                                               
83: R68         Net Loss Per Share Attributable to Common           HTML     59K 
                Stockholders - Summary of the Computation of Basic               
                and Diluted Net Loss Per Share Attributable to                   
                Common Stockholders (Details)                                    
84: R69         Net Loss Per Share Attributable to Common           HTML     32K 
                Stockholders - Schedule of Anti-Dilutive                         
                Securities Excluded from Computation of Earnings                 
                Per Share (Details)                                              
85: R70         Income Taxes - Summary of Reconciliation of         HTML     45K 
                Federal Statutory Income Tax Rate to Effective                   
                Income Tax Rate (Details)                                        
86: R71         Income Taxes - Summary of Components of Deferred    HTML     59K 
                Taxes (Details)                                                  
87: R72         Income Taxes - Additional Information (Details)     HTML     49K 
88: R73         Related Party Transactions - Additional             HTML     87K 
                Information (Details)                                            
89: R74         Employee Benefits - Additional Information          HTML     36K 
                (Details)                                                        
91: XML         IDEA XML File -- Filing Summary                      XML    172K 
94: XML         XBRL Instance -- omga-20231231_htm                   XML   1.87M 
90: EXCEL       IDEA Workbook of Financial Report Info              XLSX    172K 
15: EX-101.SCH  XBRL Taxonomy Extension Schema With Embedded         XSD   4.22M 
                Linkbases Document -- omga-20231231                              
92: JSON        XBRL Instance as JSON Data -- MetaLinks              643±  1.00M 
93: ZIP         XBRL Zipped Folder -- 0000950170-24-038094-xbrl      Zip   2.14M

‘XML’   —   IDEA XML File — Filing Summary

This Document is an IDEA XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<FilingSummary>
<Version> 3.24.1 </Version>
<ProcessingTime/>
<ReportFormat> html </ReportFormat>
<ContextCount> 189 </ContextCount>
<ElementCount> 411 </ElementCount>
<EntityCount> 1 </EntityCount>
<FootnotesReported> false </FootnotesReported>
<SegmentCount> 77 </SegmentCount>
<ScenarioCount> 0 </ScenarioCount>
<TuplesReported> false </TuplesReported>
<UnitCount> 12 </UnitCount>
<MyReports>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R1.htm </HtmlFileName>
<LongName> 100000 - Document - Document and Entity Information </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DocumentDocumentAndEntityInformation </Role>
<ShortName> Document and Entity Information </ShortName>
<MenuCategory> Cover </MenuCategory>
<Position> 1 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R2.htm </HtmlFileName>
<LongName> 100010 - Statement - Consolidated Balance Sheets </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheets </Role>
<ShortName> Consolidated Balance Sheets </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 2 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R3.htm </HtmlFileName>
<LongName> 100030 - Statement - Consolidated Balance Sheets (Parenthetical) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical </Role>
<ShortName> Consolidated Balance Sheets (Parenthetical) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 3 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R4.htm </HtmlFileName>
<LongName> 100060 - Statement - Consolidated Statements of Operations and Comprehensive Loss </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss </Role>
<ShortName> Consolidated Statements of Operations and Comprehensive Loss </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 4 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R5.htm </HtmlFileName>
<LongName> 100070 - Statement - Consolidated Statements of Stockholders' Equity </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity </Role>
<ShortName> Consolidated Statements of Stockholders' Equity </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 5 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R6.htm </HtmlFileName>
<LongName> 100080 - Statement - Consolidated Statements of Cash Flows </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows </Role>
<ShortName> Consolidated Statements of Cash Flows </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 6 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R7.htm </HtmlFileName>
<LongName> 995410 - Disclosure - Pay vs Performance Disclosure </LongName>
<ReportType> Sheet </ReportType>
<Role> http://xbrl.sec.gov/ecd/role/PvpDisclosure </Role>
<ShortName> Pay vs Performance Disclosure </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 7 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R8.htm </HtmlFileName>
<LongName> 995445 - Disclosure - Insider Trading Arrangements </LongName>
<ReportType> Sheet </ReportType>
<Role> http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements </Role>
<ShortName> Insider Trading Arrangements </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 8 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R9.htm </HtmlFileName>
<LongName> 995455 - Disclosure - Nature of the Business and Basis of Presentation </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation </Role>
<ShortName> Nature of the Business and Basis of Presentation </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 9 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R10.htm </HtmlFileName>
<LongName> 995465 - Disclosure - Summary of Significant Accounting Policies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies </Role>
<ShortName> Summary of Significant Accounting Policies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 10 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R11.htm </HtmlFileName>
<LongName> 995475 - Disclosure - Marketable Securities </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureMarketableSecurities </Role>
<ShortName> Marketable Securities </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 11 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R12.htm </HtmlFileName>
<LongName> 995485 - Disclosure - Prepaid Expenses and Other Current Assets </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets </Role>
<ShortName> Prepaid Expenses and Other Current Assets </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 12 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R13.htm </HtmlFileName>
<LongName> 995495 - Disclosure - Property and Equipment, Net </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet </Role>
<ShortName> Property and Equipment, Net </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 13 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R14.htm </HtmlFileName>
<LongName> 995505 - Disclosure - Accrued Expenses </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedExpenses </Role>
<ShortName> Accrued Expenses </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 14 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R15.htm </HtmlFileName>
<LongName> 995515 - Disclosure - Term Loan </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureTermLoan </Role>
<ShortName> Term Loan </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 15 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R16.htm </HtmlFileName>
<LongName> 995525 - Disclosure - Fair Value of Financial Instruments </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments </Role>
<ShortName> Fair Value of Financial Instruments </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 16 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R17.htm </HtmlFileName>
<LongName> 995535 - Disclosure - Commitments and Contingencies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies </Role>
<ShortName> Commitments and Contingencies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 17 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R18.htm </HtmlFileName>
<LongName> 995545 - Disclosure - License Agreements </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureLicenseAgreements </Role>
<ShortName> License Agreements </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 18 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R19.htm </HtmlFileName>
<LongName> 995555 - Disclosure - Collaboration Agreement </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAgreement </Role>
<ShortName> Collaboration Agreement </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 19 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R20.htm </HtmlFileName>
<LongName> 995575 - Disclosure - Preferred and Common Stock </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosurePreferredAndCommonStock1 </Role>
<ShortName> Preferred and Common Stock </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 20 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R21.htm </HtmlFileName>
<LongName> 995585 - Disclosure - Equity Incentive Plans </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlans </Role>
<ShortName> Equity Incentive Plans </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 21 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R22.htm </HtmlFileName>
<LongName> 995595 - Disclosure - Net Loss Per Share Attributable to Common Stockholders </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders </Role>
<ShortName> Net Loss Per Share Attributable to Common Stockholders </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 22 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R23.htm </HtmlFileName>
<LongName> 995605 - Disclosure - Income Taxes </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes </Role>
<ShortName> Income Taxes </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 23 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R24.htm </HtmlFileName>
<LongName> 995615 - Disclosure - Related Party Transactions </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactions </Role>
<ShortName> Related Party Transactions </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 24 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R25.htm </HtmlFileName>
<LongName> 995625 - Disclosure - Employee Benefits </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureEmployeeBenefits </Role>
<ShortName> Employee Benefits </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 25 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R26.htm </HtmlFileName>
<LongName> 995645 - Disclosure - Summary of Significant Accounting Policies (Policies) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies </Role>
<ShortName> Summary of Significant Accounting Policies (Policies) </ShortName>
<MenuCategory> Policies </MenuCategory>
<ParentRole> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies </ParentRole>
<Position> 26 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R27.htm </HtmlFileName>
<LongName> 995655 - Disclosure - Summary of Significant Accounting Policies (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables </Role>
<ShortName> Summary of Significant Accounting Policies (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies </ParentRole>
<Position> 27 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R28.htm </HtmlFileName>
<LongName> 995665 - Disclosure - Marketable Securities (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesTables </Role>
<ShortName> Marketable Securities (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureMarketableSecurities </ParentRole>
<Position> 28 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R29.htm </HtmlFileName>
<LongName> 995675 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables </Role>
<ShortName> Prepaid Expenses and Other Current Assets (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets </ParentRole>
<Position> 29 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R30.htm </HtmlFileName>
<LongName> 995685 - Disclosure - Property and Equipment, Net (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables </Role>
<ShortName> Property and Equipment, Net (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet </ParentRole>
<Position> 30 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R31.htm </HtmlFileName>
<LongName> 995695 - Disclosure - Accrued Expenses (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesTables </Role>
<ShortName> Accrued Expenses (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedExpenses </ParentRole>
<Position> 31 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R32.htm </HtmlFileName>
<LongName> 995705 - Disclosure - Term Loan (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureTermLoanTables </Role>
<ShortName> Term Loan (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureTermLoan </ParentRole>
<Position> 32 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R33.htm </HtmlFileName>
<LongName> 995715 - Disclosure - Fair Value of Financial Instruments (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables </Role>
<ShortName> Fair Value of Financial Instruments (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments </ParentRole>
<Position> 33 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R34.htm </HtmlFileName>
<LongName> 995725 - Disclosure - Commitments and Contingencies (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables </Role>
<ShortName> Commitments and Contingencies (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingencies </ParentRole>
<Position> 34 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R35.htm </HtmlFileName>
<LongName> 995745 - Disclosure - Equity Incentive Plans (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansTables </Role>
<ShortName> Equity Incentive Plans (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlans </ParentRole>
<Position> 35 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R36.htm </HtmlFileName>
<LongName> 995755 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables </Role>
<ShortName> Net Loss Per Share Attributable to Common Stockholders (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders </ParentRole>
<Position> 36 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R37.htm </HtmlFileName>
<LongName> 995765 - Disclosure - Income Taxes (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesTables </Role>
<ShortName> Income Taxes (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureIncomeTaxes </ParentRole>
<Position> 37 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R38.htm </HtmlFileName>
<LongName> 995775 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails </Role>
<ShortName> Nature of the Business and Basis of Presentation - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 38 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R39.htm </HtmlFileName>
<LongName> 995785 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails </Role>
<ShortName> Summary of Significant Accounting Policies - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 39 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R40.htm </HtmlFileName>
<LongName> 995795 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Each Asset Category (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLifeOfEachAssetCategoryDetails </Role>
<ShortName> Summary of Significant Accounting Policies - Summary of Estimated Useful Life of Each Asset Category (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 40 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R41.htm </HtmlFileName>
<LongName> 995805 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails </Role>
<ShortName> Marketable Securities - Summary of Marketable Securities (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 41 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R42.htm </HtmlFileName>
<LongName> 995815 - Disclosure - Marketable Securities - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails </Role>
<ShortName> Marketable Securities - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 42 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R43.htm </HtmlFileName>
<LongName> 995825 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and other Current Assets (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails </Role>
<ShortName> Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and other Current Assets (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 43 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R44.htm </HtmlFileName>
<LongName> 995835 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails </Role>
<ShortName> Property and Equipment, Net - Summary of Property and Equipment, Net (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 44 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R45.htm </HtmlFileName>
<LongName> 995845 - Disclosure - Property and Equipment, Net - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails </Role>
<ShortName> Property and Equipment, Net - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 45 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R46.htm </HtmlFileName>
<LongName> 995855 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureAccruedExpensesSummaryOfAccruedExpensesDetails </Role>
<ShortName> Accrued Expenses - Summary of Accrued Expenses (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 46 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R47.htm </HtmlFileName>
<LongName> 995865 - Disclosure - Term Loan - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails </Role>
<ShortName> Term Loan - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 47 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R48.htm </HtmlFileName>
<LongName> 995875 - Disclosure - Term Loan - Summary of Outstanding Term Loan Balance (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureTermLoanSummaryOfOutstandingTermLoanBalanceDetails </Role>
<ShortName> Term Loan - Summary of Outstanding Term Loan Balance (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 48 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R49.htm </HtmlFileName>
<LongName> 995885 - Disclosure - Term Loan - Summary of Interest Expense Recognized Related to Term loan (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureTermLoanSummaryOfInterestExpenseRecognizedRelatedToTermLoanDetails </Role>
<ShortName> Term Loan - Summary of Interest Expense Recognized Related to Term loan (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 49 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R50.htm </HtmlFileName>
<LongName> 995895 - Disclosure - Term Loan - Schedule of Principal Amount in Connection With Term Loan (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureTermLoanScheduleOfPrincipalAmountInConnectionWithTermLoanDetails </Role>
<ShortName> Term Loan - Schedule of Principal Amount in Connection With Term Loan (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 50 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R51.htm </HtmlFileName>
<LongName> 995905 - Disclosure - Fair Value of Financial Instruments - Summary of Fair Value of Financial Instruments (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValueOfFinancialInstrumentsDetails </Role>
<ShortName> Fair Value of Financial Instruments - Summary of Fair Value of Financial Instruments (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 51 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R52.htm </HtmlFileName>
<LongName> 995915 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails </Role>
<ShortName> Fair Value of Financial Instruments - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 52 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R53.htm </HtmlFileName>
<LongName> 995935 - Disclosure - Fair Value of Financial Instruments - Summary of Significant Quantitative Inputs Used to Determine Valuation of Success Fee Obligation (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfSignificantQuantitativeInputsUsedToDetermineValuationOfSuccessFeeObligationDetails </Role>
<ShortName> Fair Value of Financial Instruments - Summary of Significant Quantitative Inputs Used to Determine Valuation of Success Fee Obligation (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 53 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R54.htm </HtmlFileName>
<LongName> 995945 - Disclosure - Fair Value of Financial Instruments - Summary of Fair Values of Success Fee Obligation (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFairValuesOfSuccessFeeObligationDetails </Role>
<ShortName> Fair Value of Financial Instruments - Summary of Fair Values of Success Fee Obligation (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 54 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R55.htm </HtmlFileName>
<LongName> 995955 - Disclosure - Commitments and Contingencies - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails </Role>
<ShortName> Commitments and Contingencies - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 55 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R56.htm </HtmlFileName>
<LongName> 995965 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Expense (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetails </Role>
<ShortName> Commitments and Contingencies - Summary of Components of Lease Expense (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 56 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R57.htm </HtmlFileName>
<LongName> 995975 - Disclosure - Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term And Discount Rate Related to Leases (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfWeightedAverageRemainingLeaseTermAndDiscountRateRelatedToLeasesDetails </Role>
<ShortName> Commitments and Contingencies - Summary of Weighted Average Remaining Lease Term And Discount Rate Related to Leases (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 57 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R58.htm </HtmlFileName>
<LongName> 995985 - Disclosure - Commitments and Contingencies - Summary of Supplemental Cash Flow Information Relating to Leases (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalCashFlowInformationRelatingToLeasesDetails </Role>
<ShortName> Commitments and Contingencies - Summary of Supplemental Cash Flow Information Relating to Leases (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 58 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R59.htm </HtmlFileName>
<LongName> 995995 - Disclosure - Commitments and Contingencies - Summary of Estimated Minimum Lease Payments (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfEstimatedMinimumLeasePaymentsDetails </Role>
<ShortName> Commitments and Contingencies - Summary of Estimated Minimum Lease Payments (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 59 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R60.htm </HtmlFileName>
<LongName> 996005 - Disclosure - License Agreements - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails </Role>
<ShortName> License Agreements - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 60 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R61.htm </HtmlFileName>
<LongName> 996015 - Disclosure - Collaboration Agreement - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureCollaborationAgreementAdditionalInformationDetails </Role>
<ShortName> Collaboration Agreement - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 61 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R62.htm </HtmlFileName>
<LongName> 996025 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails </Role>
<ShortName> Redeemable Convertible Preferred Stock - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 62 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R63.htm </HtmlFileName>
<LongName> 996035 - Disclosure - Preferred and Common Stock - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosurePreferredAndCommonStockAdditionalInformationDetails </Role>
<ShortName> Preferred and Common Stock - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 63 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R64.htm </HtmlFileName>
<LongName> 996045 - Disclosure - Equity Incentive Plans - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetails </Role>
<ShortName> Equity Incentive Plans - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 64 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R65.htm </HtmlFileName>
<LongName> 996055 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockbasedCompensationExpenseDetails </Role>
<ShortName> Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 65 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R66.htm </HtmlFileName>
<LongName> 996065 - Disclosure - Equity Incentive Plans - Summary of Assumptions Used in Black-Scholes Option-pricing Model for Stock Options (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfAssumptionsUsedInBlackscholesOptionpricingModelForStockOptionsDetails </Role>
<ShortName> Equity Incentive Plans - Summary of Assumptions Used in Black-Scholes Option-pricing Model for Stock Options (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 66 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R67.htm </HtmlFileName>
<LongName> 996075 - Disclosure - Equity Incentive Plans - Summary of Option Activity (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfOptionActivityDetails </Role>
<ShortName> Equity Incentive Plans - Summary of Option Activity (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 67 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R68.htm </HtmlFileName>
<LongName> 996085 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of the Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfComputationOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails </Role>
<ShortName> Net Loss Per Share Attributable to Common Stockholders - Summary of the Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 68 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R69.htm </HtmlFileName>
<LongName> 996095 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails </Role>
<ShortName> Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 69 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R70.htm </HtmlFileName>
<LongName> 996105 - Disclosure - Income Taxes - Summary of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfReconciliationOfFederalStatutoryIncomeTaxRateToEffectiveIncomeTaxRateDetails </Role>
<ShortName> Income Taxes - Summary of Reconciliation of Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 70 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R71.htm </HtmlFileName>
<LongName> 996115 - Disclosure - Income Taxes - Summary of Components of Deferred Taxes (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesSummaryOfComponentsOfDeferredTaxesDetails </Role>
<ShortName> Income Taxes - Summary of Components of Deferred Taxes (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 71 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R72.htm </HtmlFileName>
<LongName> 996125 - Disclosure - Income Taxes - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails </Role>
<ShortName> Income Taxes - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 72 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R73.htm </HtmlFileName>
<LongName> 996135 - Disclosure - Related Party Transactions - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails </Role>
<ShortName> Related Party Transactions - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 73 </Position>
</Report>
<Report instance="omga-20231231.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R74.htm </HtmlFileName>
<LongName> 996145 - Disclosure - Employee Benefits - Additional Information (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://omegatherapeutics.com/20231231/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformationDetails </Role>
<ShortName> Employee Benefits - Additional Information (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 74 </Position>
</Report>
<Report>
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<LongName> All Reports </LongName>
<ReportType> Book </ReportType>
<ShortName> All Reports </ShortName>
</Report>
</MyReports>
<Logs>
<Log type="Warning"> [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: omga:NumberOfSharedSpaceArrangements, us-gaap:LeaseExpirationDate1, us-gaap:OperatingLossCarryforwardsExpirationDate - omga-20231231.htm 8 </Log>
</Logs>
<InputFiles>
<File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="omga-20231231.htm"> omga-20231231.htm </File>
<File> omga-20231231.xsd </File>
</InputFiles>
<SupplementalFiles>
<File> img112225459_0.jpg </File>
<File> img112225459_1.jpg </File>
<File> img112225459_10.jpg </File>
<File> img112225459_11.jpg </File>
<File> img112225459_12.jpg </File>
<File> img112225459_13.jpg </File>
<File> img112225459_14.jpg </File>
<File> img112225459_15.jpg </File>
<File> img112225459_16.jpg </File>
<File> img112225459_17.jpg </File>
<File> img112225459_18.jpg </File>
<File> img112225459_19.jpg </File>
<File> img112225459_2.jpg </File>
<File> img112225459_20.jpg </File>
<File> img112225459_21.jpg </File>
<File> img112225459_3.jpg </File>
<File> img112225459_4.jpg </File>
<File> img112225459_5.jpg </File>
<File> img112225459_6.jpg </File>
<File> img112225459_7.jpg </File>
<File> img112225459_8.jpg </File>
<File> img112225459_9.jpg </File>
</SupplementalFiles>
<BaseTaxonomies>
<BaseTaxonomy items="580"> http://fasb.org/us-gaap/2023 </BaseTaxonomy>
<BaseTaxonomy items="39"> http://xbrl.sec.gov/dei/2023 </BaseTaxonomy>
<BaseTaxonomy items="4"> http://xbrl.sec.gov/ecd/2023 </BaseTaxonomy>
</BaseTaxonomies>
<HasPresentationLinkbase> false </HasPresentationLinkbase>
<HasCalculationLinkbase> false </HasCalculationLinkbase>
</FilingSummary>

13 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/11/23  Omega Therapeutics, Inc.          8-K:5,9    12/11/23   11:510K                                   Donnelley … Solutions/FA
 9/22/23  Omega Therapeutics, Inc.          8-K:1,2     9/22/23   11:258K                                   Donnelley … Solutions/FA
 8/03/23  Omega Therapeutics, Inc.          8-K:1,2,9   8/03/23   13:481K                                   Donnelley … Solutions/FA
 8/03/23  Omega Therapeutics, Inc.          10-Q        6/30/23   81:10M                                    Donnelley … Solutions/FA
 7/13/23  Omega Therapeutics, Inc.          8-K:1,9     7/11/23   13:1M                                     Donnelley … Solutions/FA
 3/01/23  Omega Therapeutics, Inc.          10-K       12/31/22   91:15M                                    Donnelley … Solutions/FA
 2/23/23  Omega Therapeutics, Inc.          8-K:1,9     2/22/23   12:363K                                   Donnelley … Solutions/FA
 5/04/22  Omega Therapeutics, Inc.          10-Q        3/31/22   84:9.8M                                   Donnelley … Solutions/FA
 3/10/22  Omega Therapeutics, Inc.          10-K       12/31/21   96:20M                                    Donnelley … Solutions/FA
12/21/21  Omega Therapeutics, Inc.          8-K:1,2,9  12/20/21   11:302K                                   Donnelley … Solutions/FA
 8/03/21  Omega Therapeutics, Inc.          8-K:5,9     8/03/21    3:233K                                   Donnelley … Solutions/FA
 7/26/21  Omega Therapeutics, Inc.          S-1/A                 19:7.2M                                   Donnelley … Solutions/FA
 7/09/21  Omega Therapeutics, Inc.          S-1                   15:6.1M                                   Donnelley … Solutions/FA
↑Top
Filing Submission 0000950170-24-038094   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., May 14, 4:09:29.2am ET